Nasal absorption of hydroxocobalamin in healthy elderly adults

British Journal of Clinical Pharmacology

Volumn 45, Issue 1, 1998, Pages 83-86

  Van Asselt, D Z B ^a   Merkus, F W H M ^b   Russel, F G M ^a   Hoefnagels, W H L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Elderly volunteers; Hydroxocobalamin (vitamin B12) nasal spray; Nasal absorption; Plasma cobalamin concentrations

Indexed keywords

HYDROXOCOBALAMIN;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; LIGAND BINDING; NORMAL HUMAN; NOSE MUCOSA; PERNICIOUS ANEMIA; PRIORITY JOURNAL; VITAMIN DEFICIENCY;

ABSORPTION; ADMINISTRATION, INHALATION; AGED; CROSS-OVER STUDIES; FEMALE; HEMATINICS; HUMANS; HYDROXOCOBALAMIN; MALE; NASAL MUCOSA;

EID: 0031907494     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00642.x     Document Type: Article

References (25)

1. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60: 2-11.
2. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc 1992; 40: 1197-1204.
3. Babior BM, Bunn HF. Megaloblastic anemia. In Harrison's principles of internal medicine, 12. ed., Wilson JD, Braunwald E, Isselbacher KJ, eds, New York: McGraw-Hill, Inc., 1991: 1523-1529.
4. Freedman ML. Blood disorders and their management in old age. In Textbook of geriatric medicine and gerontology, 4. ed., Brocklehurst JC, Tallis RC, Fillit HM, eds, Edinburgh: Churchill Livingstone, 1992: 859-922.
5. West R. Activity of vitamin B12 in Addisonian pernicious anemia. Science NY 1948; 107: 398.
6. Israëls MCG, Shubert S. The treatment of pernicious anemia by insufflation of vitamin B12. Lancet 1954; i: 341-343.
7. Monto RW, Rebuck JW, Brennan MJ. Crystalline B12 inhalation therapy in pernicious anemia. Am J Med Sci 1953; 225: 113-119.
8. Monto KW, Rebuck JW. Nasal instillation and inhalation of crystalline vitamin B12 in pernicious anemia. Arch Intern Med 1954; 93: 219-230.
9. Romeo VD, Sileno A, Wenig DN. Intranasal cyanocobalamin. JAMA 1992; 268: 1268-1269.
10. Waife SO, Jansen CJ, Crabtree RE, Grinnan EL, Fouts PJ. Oral vitamin B12 without intrinsic factor in the treatment of pernicious anemia. Ann Intern Med 1963; 58: 810-817.
11. Brody EA, Estren S, Wasserman LR. Treatment of pernicious anemia by oral administration of vitamin B12 without added intrinsic factor. New Engl J Med 1959; 260: 361-367.
12. Waife SO, Jansen CJ, Crabtree RE, Grinnan EL, Fouts PJ. Oral vitamin B12 without intrinsic factor in the treatment of pernicious anemia. Ann Int Med 1963; 58: 810-817.
13. Lederle FA. Oral cyanocobalamin for pernicious anemia: medicine's best kept secret? JAMA 1991; 265: 94-95.
14. Reidenberg MM. Cyanocobalamin - a case for withdrawal. J R Soc Med 1993; 86: 309.
15. Hall CA, Begley JA, Green Colligan PD. The availability of therapeutic hydroxocobalamin to cells. Blood 1984; 63: 335-341.
16. Freeman AG. Cyanocobalamin - a case for withdrawal. J R Soc Med 1992; 85: 686-687.
17. Linnell JC, Matthews DM, England JM. Therapeutic misuse of cyanocobalamin. Lancet 1978; ii: 1053-1054.
18. Merkus FWHM. A pharmaceutical composition for the intranasal administration of hydroxocobalamin. International Patent Appl. WO 95/17164. 1995: 1-10.
19. Fisher AN, Brown K, Davis SS, Parr GD, Smith DA. The effect of molecular size on the nasal absorption of water-soluble compounds in the albino rat. J Pharm Pharmacol 1987; 39: 357-362.
20. McMartm C, Hutchinson LE, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 1987; 76: 535-540.
21. Tonnesen P, Thim L, Nexo E. Epidermal growth factor and haptocomn in nasal secretion. Scand J Clin Lab Invest 1990; 50: 187-194.
22. Skouby AP. Retention and distribution of B12 acitivity and requirement for B12 following parenteral administration of hydroxocobalamin (Vibiden). Acta Med Scand 1966; 180: 95-105.
23. Hertz H, Ostergaard Kristensen HP, Hoff-Jorgensen E. Studies on vitamin B12 retention. Scand J Haematol 1964; 1: 1-15.
24. Killander A, Schilling RF. Studies on hydroxocobalamin. J Lab Clin Med 1961; 57: 553-561.
25. Bruins Slot W, Merkus FWHM, Tytgat GNJ. Hydroxocobalamin intranasally in patients with Crohn's disease and low serum B12 levels. Gastroenterology 1996; 110: A874.